For over twenty years, New York Oncology Hematology has participated in clinical trials and has played a pivotal role in the FDA approval process of 24 new anticancer drugs. We are currently collaborating with leading pharmaceutical and biotechnology companies working with chemotherapy, immunotherapy, and stem cell transplantation.

We have a unique research infrastructure that includes a dedicated research staff and a standardized Institutional Review Board approval process. This highly efficient organization helps speed drugs from the research lab into patient care, as quickly as possible while providing the highest quality care to our patients.

NYOH participates in Phase I/II and III clinical trials. Trials include all major solid tumor types, hematologic malignancies and supportive care. Our US Oncology affiliation provides us with a robust panel of clinical trial options for our patients. We also participate in National Cancer Institute (NCI) sponsored research through the Eastern Cooperative Oncology Group (ECOG), and  the National Surgical Adjuvant Breast and Bowel Project (NSABP).

 The End of Cancer Begins with Research.  

CURRENT OPEN CLINICAL TRIALS AT NYOH:

Why Do Research?
Research improves the current state of cancer care by finding better ways to prevent and treat cancer.
Research improves the quality of life and extends survival for all who are diagnosed with cancer.
Research provides patients access to new, potentially more effective therapies which are not otherwise available.


What Are Clinical Trials?

Clinical trials are research studies that involve people.  
These studies occur after laboratory and animal testing has been completed.
Clinical trials are the only way new cancer treatments can be tested for efficacy and safety before being made available to the public.
Each study tries to answer specific scientific questions and find better ways to prevent, diagnose, or treat cancer.


Why Are Clinical Trials Important?

Cancer affects us all.  Every 25 seconds a man, woman or child in the U.S. is diagnosed with cancer. 
About 556,500 Americans are expected to die from cancer this year – more than 1,500 people a day.
Clinical trials contribute to knowledge and progress against cancer.
Today’s standard treatments are based on previous clinical trial results. 
Because of progress made, many people with cancer are living longer.

In addition to improved survival rates, clinical trials have contributed to:
 
Lower recurrence rates for many cancers
 New treatment approaches for cancers that had no effective therapy
 Fewer side effects and better quality of life

The more people that participate in clinical trials, the faster we can answer critical research questions that will lead to better treatments.

Cancer Clinical Trial Participation
Only about 3% of adult cancer patients take part in clinical trials.
Over 80% of children with cancer participate in clinical trials. Why do so many children participate?

         
Trials are considered standard of care in pediatric oncology.
Result: Cure rates for childhood cancers now exceed 75%.  

Types of Cancer Clinical Trials
Treatment trials involve new investigational treatments such as new anticancer drugs.
Prevention trials involve new approaches to prevent cancer or prevent a recurrence of cancer.
Screening trials investigate the best way to diagnose cancer, especially in the early stages.
Quality-of-life/cancer control trials explore ways to improve the comfort and quality-of-life of cancer patients.
 

The Protocol: A Trial’s Action Plan
A protocol specifically outlines the study’s purpose.
Defines the study size and number of participants.
Describes the plan of care and collection of data.
Carefully developed / reviewed by the Principal Investigator and the sponsoring organization.
Reviewed and approved by an Institutional Review Board (IRB).
Ensures that trial procedures are consistently carried out.
 

Institutional Review Board (IRB)
IRBs review that:

Risks to participants are minimized
Risks are reasonable in relation to anticipated benefits
Selection of participants is equitable
Informed consent is sought for each participant
Informed consent is appropriately documented
Data collection is monitored to ensure safety
Privacy and confidentiality are protected
 

Why consider a Clinical Trial?
- Alternative to standard treatment
- May provide early access today to the treatments of tomorrow
- Monitored very closely even after the treatment is completed
- Only through clinical trials do we learn to prevent, better treat, and cure cancer AND help others in the future!

For further information on clinical trials, please contact us at these locations:
NYOH - Albany                                                                   NYOH - Latham
400 Patroon Creek Blvd., Suite 1                                         1003 Loudon Rd.
Albany, NY 12206                                                                PO Box 610     
(518) 489-0044                                                                    Latham, NY 12110
Michele Butler, Research Manager                                      (518) 786-3122
                                                                                             Kathy Disisto, Research Coordinator

NYOH - Albany Medical Center                                        
NYOH - Rexford
43 New Scotland Ave                                                          896 Riverview Rd.
Albany, NY 12208                                                                Rexford, NY 12148
(518) 262-6696                                                                    (518) 399-4600
Joanna Walsh, Research Coordinator                                 Darlene Pafundi, Research Coordinator

NYOH -Amsterdam                                                          NYOH - Troy 
1700 Riverfront Center                                                       2200 Burdett Ave., Suite 106
Amsterdam, NY 12010                                                       Troy, NY 12180
(518) 843-0020                                                                   (518) 272-2097
Laura Marion, Research Coordinator                                  Mary Bowen, Research Coordinator

NYOH - Hudson
69 Prospect Ave.
Hudson, NY 12534
(518) 822-8484
Joanne Wagman, Research Coordinator

 

In 2006, New York Oncology Hematology was the proud recipient of two national prestigious awards:

American Society of Clinical Oncology (ASCO) Community Research Award

and US Oncology “Outstanding Growth in Accruals”

 

For more information on clinical trials, please visit www.clinicaltrials.gov